On Tuesday the European Commission adopted a plan to revise its rules on clinical trials in a move welcomed by most industry stakeholders, including Association of Clinical Research Organisations' (ACRO) executive director, Doug Peddicord, who applauded the efforts in a statement released last night.
"ACRO is especially pleased that the Commission has followed our recommendations regards the coordinated assessment of clinical trials, streamlined reporting and increased transparency" Peddicord said, adding that the organisation commends the flexible approach to oversight of trials in multiple EU member States set out in the proposals.
This echoed comments by the European Federation of Pharmaceutical Industries and Professionals (EFPIA) which said: "The Commission's proposal provides a unique opportunity to create a competitive European medical research environment for the next 20 years capable of supporting the discovery and development of tomorrow’s treatments for the benefit of European patients."
What do you think?
So ACRO backs the plan, but what does the wider CRO sector think? Do you think change is needed? Do you think the EC's comments about the Clinical Trial Directive's impact on research in the EU is accurate? Do you think the reofrms will have the desired affect?
Please let Outsourcing-Pharma.com know by answering this anonymised poll.